<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001927.pub2" GROUP_ID="STROKE" ID="828199093014033719" MERGED_FROM="" MODIFIED="2008-09-04 12:44:57 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-09-04 12:44:57 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks</TITLE>
<CONTACT MODIFIED="2008-09-04 12:44:57 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="9230" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><LAST_NAME>Hart</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Medicine (Neurology)</POSITION><EMAIL_1>hartr@uthscsa.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neurology, Department of Medicine</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Drive</ADDRESS_1><CITY>San Antonio</CITY><ZIP>78284-7883</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 6175161</PHONE_1><PHONE_2>+1 210 5920404</PHONE_2><FAX_1>+1 210 5674659</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-04 12:44:57 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="CC0260ED82E26AA2014E8D67A13AC6AB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><MIDDLE_INITIALS>I</MIDDLE_INITIALS><LAST_NAME>Aguilar</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Instructor in Neurology</POSITION><EMAIL_1>aguilar.maria@mayo.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology, Division of Cerebrovascular Disease</DEPARTMENT><ORGANISATION>Mayo Clinic Scottsdale</ORGANISATION><ADDRESS_1>13400 East Shea Boulevard</ADDRESS_1><CITY>Scottsdale</CITY><ZIP>85259</ZIP><REGION>Arizona</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 480 301 8100</PHONE_1><FAX_1>+1 480 301 8451</FAX_1></ADDRESS></PERSON><PERSON ID="9230" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><LAST_NAME>Hart</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Medicine (Neurology)</POSITION><EMAIL_1>hartr@uthscsa.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neurology, Department of Medicine</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Drive</ADDRESS_1><CITY>San Antonio</CITY><ZIP>78284-7883</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 6175161</PHONE_1><PHONE_2>+1 210 5920404</PHONE_2><FAX_1>+1 210 5674659</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-04 11:12:43 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="29" MONTH="9" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="6" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-04 11:13:19 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-04 11:13:17 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-04 11:13:17 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="29" MONTH="9" YEAR="2004"/>
<DESCRIPTION>
<P>In this update, all-cause mortality was added as an outcome. Compared with control, adjusted-dose warfarin reduced death in atrial fibrillation patients.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-04 11:38:20 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-09-04 11:26:40 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-09-04 11:26:40 +0100" MODIFIED_BY="Hazel Fraser">Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-04 11:26:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Oral anticoagulants prevent stroke and death in people with atrial fibrillation. Atrial fibrillation is an irregularity of the heartbeat that leads to blood clots forming in the upper chambers of the heart (the atria). These clots can break free and travel through the blood stream to the brain and cause a stroke. Anticoagulant drugs, such as warfarin, slow blood clotting. The degree of inhibition of blood clotting during warfarin treatment is measured by a blood test called the international normalized ratio (INR). Dosages of warfarin that lead to INRs of 2.0 to 2.6 reduce death and stroke when given to patients with atrial fibrillation. Oral anticoagulants can cause bleeding into the brain and elsewhere. However, provided that there is careful control of dosage (requiring INR measurements at least monthly with warfarin), the risk of serious bleeding is low. The decision about whether or not to use oral anticoagulants in patients with atrial fibrillation is guided by a number of factors, including the individual's risk of stroke, which varies widely among patients with atrial fibrillation. Most people with atrial fibrillation should be considered for treatment with oral anticoagulants based on their risk of stroke, ability to tolerate anticoagulation without bleeding, and access to adequate anticoagulation monitoring.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-09-04 11:33:21 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Non-valvular atrial fibrillation (AF) is associated with an increased risk of stroke mediated by embolism of stasis-precipitated thrombi from the left atrial appendage. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-09-04 11:32:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>To characterize the efficacy and safety of oral anticoagulants (OACs) for the primary prevention of stroke in patients with chronic AF.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-09-04 11:13:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched in June 2004). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>Issue 4, 2004), MEDLINE (1966 to June 2004), and the reference lists of recent review articles. We also contacted the Atrial Fibrillation Collaboration and experts working in the field to identify unpublished and ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized controlled trials comparing OACs with control in patients with chronic non-valvular atrial fibrillation and no history of transient ischemic attack (TIA) or stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-09-04 11:13:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>Trials for inclusion were independently selected by two authors who also extracted each outcome and double-checked the data. The Peto method was used for combining odds ratios. All analysis were, as far as possible, intention-to-treat. Since the published results of four trials included 3% to 8% of participants with prior stroke or TIA, unpublished results excluding these participants were obtained from the Atrial Fibrillation Investigators.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-09-04 11:33:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Of 2313 participants without prior cerebral ischemia from five randomized trials, the mean age was 69 years. Participant features and study quality were similar between trials: the OAC in all five trials was warfarin. About half of participants (N = 1154) were randomized to adjusted-dose warfarin with mean achieved INRs ranging between 2.0 to 2.6. During 1.5 years mean follow up, warfarin was associated with large, highly statistically significant reductions in all strokes (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.26 to 0.59), ischemic stroke (OR 0.34, 95% CI 0.23 to 0.52), all disabling or fatal stroke (OR 0.47, 95% CI 0.28 to 0.80), death (OR 0.69, 95% CI 0.50 to 0.94) and the combined endpoint of all stroke, myocardial infarction or vascular death (OR 0.56, 95% CI 0.42 to 0.76). The observed rates of intracranial and extracranial hemorrhage were not significantly increased by OAC therapy, but the confidence intervals were wide.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-09-04 11:14:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>Treatment with adjusted-dose warfarin to achieved INRs of 2 to 3 reduces stroke, disabling or fatal stroke, and death for patients with non-valvular AF. The benefits were not substantially offset by increased bleeding among these participants in randomized clinical trials. Limitations include relatively short follow up and imprecise estimates of bleeding risks from the selected participants enrolled in the trials. For primary prevention of stroke in AF patients, about 25 strokes and about 12 disabling or fatal strokes would be prevented yearly for every 1000 atrial fibrillation patients given OACs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-04 11:38:20 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-09-04 11:14:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-valvular atrial fibrillation (AF) is a common cardiac arrhythmia, affecting about 0.7% of the general population (<LINK REF="REF-Feinberg-1995" TYPE="REFERENCE">Feinberg 1995</LINK>; <LINK REF="REF-Go-2001" TYPE="REFERENCE">Go 2001</LINK>). Its prevalence increases with age: about 5% of people over age 65 years and 10% of people over age 80 years suffer AF (<LINK REF="REF-Feinberg-1995" TYPE="REFERENCE">Feinberg 1995</LINK>). AF is the most common cause of cardioembolic stroke and is a powerful independent risk factor for cerebral ischemia. It is associated with about 16% of all ischemic strokes and is a frequent cause of disabling stroke in the elderly, particularly in women (<LINK REF="REF-Wolf-1991" TYPE="REFERENCE">Wolf 1991</LINK>). The overall risk of stroke among non-anticoagulated patients with AF without prior stroke or TIA was about 4% per year among participants in clinical trials (<LINK REF="REF-AFI-1994" TYPE="REFERENCE">AFI 1994</LINK>) and 2.5% per year in a large outpatient cohort (<LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>).</P>
<P>The rate of stroke varies widely, depending on coexisting cardiovascular disorders. Identification of subgroups of AF patients with relatively high versus low absolute rates of stroke is important for selecting the appropriate prophylactic therapy. Prospective studies have shown that age, hypertension, prior TIA or stroke, diabetes, congestive heart failure and female gender are independently predictive of stroke in AF patients and significantly increase the stroke risk (<LINK REF="REF-Gage-2001" TYPE="REFERENCE">Gage 2001</LINK>; <LINK REF="REF-Hart-1999" TYPE="REFERENCE">Hart 1999</LINK>; <LINK REF="REF-Wang-2003" TYPE="REFERENCE">Wang 2003</LINK>).</P>
<P>This systematic review includes all randomized trials of oral anticoagulants (OACs) versus control for primary prevention of stroke in patients with non-valvular AF. OACs have traditionally consisted of vitamin K antagonists (i.e. warfarin and other coumarins). Recently, OACs that work by other mechanisms (e.g. ximelagatran and other direct thrombin inhibitors) have been introduced into clinical use. Our goals are to determine whether there is clear evidence that OAC treatment is efficacious and safe in these patients and to characterize the magnitude of benefit.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-09-04 11:14:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>To characterize the effect of treatment with long-term OACs on major vascular events in patients with chronic non-valvular AF and no history of stroke or TIA. Our hypotheses were as follows.<BR/>(1) OACs compared to control would reduce ischemic events: ischemic strokes, myocardial infarction (MI), systemic emboli, and vascular death.<BR/>(2) OACs compared to control would increase bleeding events: intracranial hemorrhage and major extracranial hemorrhage.<BR/>(3) OACs compared to control would decrease clinically relevant combinations of ischemic and bleeding events: all stroke (ischemic and hemorrhagic), disabling or fatal stroke (ischemic and hemorrhagic), and the composite of all stroke, MI or vascular death.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-04 11:38:20 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-09-04 11:15:04 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES MODIFIED="2008-09-04 11:14:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>We sought to identify all unconfounded, randomized trials in which long-term treatment (more than four weeks) with OACs was compared with control or placebo in patients with chronic non-valvular AF. Trials in which the intervention was masked (i.e. double-blinded) and those in which the intervention was given open label were considered. Trials involving iatrogenic cardioversion for recent-onset AF were not included. Because the efficacy of warfarin is well established to be related to the intensity of anticoagulation (<LINK REF="REF-Hart-1998" TYPE="REFERENCE">Hart 1998</LINK>; <LINK REF="REF-Hylek-2003" TYPE="REFERENCE">Hylek 2003</LINK>; <LINK REF="REF-Oden-2005" TYPE="REFERENCE">Oden 2005</LINK>) trials testing vitamin K antagonists in which the mean INR was not prolonged beyond the normal range were excluded. Trials in which antiplatelet therapy was combined with OAC were not included (e.g. <LINK REF="STD-SAFT" TYPE="STUDY">SAFT</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-09-04 11:14:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Participants with AF documented by electrocardiogram (ECG), either intermittent (i.e. paroxysmal) or sustained (i.e. constant) were included. Those with prior stroke or TIA at anytime before study entry were not included in the primary analysis; those with mitral stenosis or prosthetic cardiac valves were also not included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral vitamin K antagonists (warfarin and congeners) with the intensity of anticoagulation dose-adjusted using the prothrombin time ratio (PTR) or International Normalized Ratio (INR) and orally active direct thrombin inhibitors (e.g. ximelagatran) were considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-09-04 11:15:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>Earlier versions of this review included analyses of nine different outcomes. For this review we have added the outcome 'all cause mortality'. Furthermore, we were asked by the Cochrane Stroke Group Editorial Board to specify a primary outcome. Since we were aware of the results of previous analyses, this section is potentially subject to data-dependent selection bias. On the other hand, in our opinion, the most clinically-relevant outcome is 'all strokes'.</P>
<P>(1) All strokes (ischemic and hemorrhagic) was the primary outcome.<BR/>(2) Ischemic strokes (including both fatal and non-fatal). Diagnosis based on clinical features not requiring confirmation by neuroimaging. Asymptomatic brain infarcts detected on neuroimaging were not included. Hemorrhagic transformation of ischemic strokes were considered with ischemic strokes.<BR/>(3) All disabling or fatal stroke (including both ischemic and hemorrhagic). Strokes were deemed fatal when death ensued within 30 days of onset from the consequences of stroke. 'Disabling' relied on varying criteria between studies. From the Atrial Fibrillation Investigators database, the category of 'stroke with residual deficit' was taken as disabling stroke, defined as neurological deficits impairing function that persisted one to three months after stroke onset.<BR/>(4) Myocardial infarction (MI) (fatal and non-fatal). The diagnosis of MI was usually based upon electrocardiographic changes, elevation of enzymes or post-mortem examination.<BR/>(5) Systemic (i.e. non-central nervous system) emboli. Symptomatic cardioembolic arterial occlusions involving areas other than the brain. Non-cardioembolic arterial occlusions were not included, when so identified, nor was pulmonary embolism.<BR/>(6) All intracranial hemorrhage. This included intraparenchymal, subdural and epidural hematomas, and subarachnoid hemorrhage based on clinical diagnosis by the investigators and usually confirmed by computerized tomography (CT) scan or post mortem.<BR/>(7) Major extracranial hemorrhage. Criteria varied between the studies considered in this analysis. From the AFI database, those which required transfusion of two or more units of red blood cells, hospitalization, or invasive procedures to control bleeding and those that resulted in death or permanent functional impairment (e.g. blindness) were included.<BR/>(8) Vascular death. These consisted of death due to stroke, heart disease, hemorrhage and sudden deaths of unknown cause.<BR/>(9) Composite outcome: all stroke (disabling and non-disabling), MI or vascular death.<BR/>(10) All cause mortality: death from any cause (vascular and non-vascular) within 30 days from onset of stroke symptoms. For this outcome, results of published data, which included about 6% of patients with prior stroke or TIA, were used.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-04 11:28:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in June 2004, using a search strategy designed to identify all relevant trials. We independently searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 4, 2004) combining 'atrial fibrillation' with 'randomized trial'. In addition, we searched MEDLINE (1966 to June 2004), not restricted to any languages, using the text words of 'atrial fibrillation' and stroke combined individually with anticoagulation, antithrombotic, clinical trial, and embolism. The reference lists of recent review articles were reviewed. We also contacted the Atrial Fibrillation Collaboration and experts working in the field to identify unpublished and ongoing trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-04 11:38:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two authors independently assessed trials for potential inclusion, and abstracted the outcomes of interest from published sources. One trial was published in Turkish (<LINK REF="STD-TAFT" TYPE="STUDY">TAFT</LINK>) and was translated. The inclusion and exclusion criteria, method of randomization, masked versus open-label intervention, intensity of anticoagulation and method of monitoring, antithrombotic agents in the control group, losses to follow up, adherence to assigned therapy, and intention-to-treat analysis were assessed and extracted using a data extraction form. Differences were resolved by conjoint review of the data and discussion.</P>
<P>We initially extracted data about the outcomes of interest from published results of trials meeting the inclusion criteria. A few (3% to 8%) participants with prior stroke or TIA (usually occurring months or years before entry) were included in each of the trials, and outcomes for these participants were not separately reported except for <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>. Hence, to permit the principal analyses to be restricted to primary prevention, we obtained unpublished data from the Atrial Fibrillation Investigators database (with the permission of the <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>, <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>, <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>, and <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK> investigators), excluding those with prior stroke or TIA and using an intention-to-treat paradigm. The Atrial Fibrillation Investigators have pooled results from individual patient data from multiple randomized clinical trials (<LINK REF="REF-AFI-1994" TYPE="REFERENCE">AFI 1994</LINK>; <LINK REF="REF-van-Walraven-2002" TYPE="REFERENCE">van Walraven 2002</LINK>). The Atrial Fibrillation Investigators' database was also used for the combined outcome of all stroke, MI or vascular death, which was not available in published sources.</P>
<P>Treatment effect was calculated using fixed-effect model (Peto method) and relative reductions calculated for each outcome. Heterogeneity between included trials was assessed using a standard chi-squared test. Our intention-to-treat analysis included all events observed according to originally-assigned treatment (i.e. events occurring in those off-therapy were counted). Participants who were lost to follow up after randomization were not identified in the Atrial Fibrillation Investigators' database and not uniformly reported in published reports, and sensitivity analysis that considered those lost to follow up could not be carried out. The fraction of participants lost to follow up was low (range 0% to 3%) when reported in three trials (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; SPINAF) (this was not reported in two trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>)), suggesting a negligible potential for biasing estimates of treatment efficacy. The absolute risk reduction was divided by mean follow-up exposure to yield the annual absolute risk reduction.</P>
<P>In this revision, we elected to include only a single subgroup analysis comparing double masked (<LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) with open trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>). The subgroup analysis was performed using the method of Deeks at al (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). The earlier version of this review included a subgroup analysis with the <LINK REF="STD-EAFT" TYPE="STUDY">EAFT</LINK> (a secondary prevention trial). In response to editorial comments this was removed.<BR/>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-04 11:29:34 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-09-04 11:18:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>Five randomized trials were included in the main analyses concerning primary prevention, three conducted in the United States (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) and one each in Canada (<LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>) and Denmark (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>). All were initiated in the mid 1980s and were concluded between 1988 and 1992. One randomized trial testing vitamin K antagonists (VKA) versus control for primary prevention in nonvalvular AF was excluded (<LINK REF="STD-TAFT" TYPE="STUDY">TAFT</LINK>) because 51% of the randomized patients were excluded from the published results. No additional qualifying trials are awaiting assessment to our knowledge.</P>
<P>The mean age of participants was 67 to 68 years old in four trials (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>), and 74 years old in one trial (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>). The overall mean age was 69 years, with 20% of participants over 75 years old. In four trials, men composed 54% to 75% of participants (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>), while one trial included only men (SPINAF); overall, 74% were men. A history of hypertension was present in about 45%, diabetes mellitus and prior MI each in about 15%, with no major differences between trials. All trials excluded those with major cardiac valvular disease or with perceived contraindications to VKA therapy. All trials included a few participants (3% to 8%) with prior stroke or TIA, usually occurring months or years before entry. Two trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) did not enrol patients with intermittent (i.e. paroxysmal) AF. Overall, the clinical features of participants were similar in these trials.</P>
<P>The intensity of anticoagulation was adjusted using the PTR in three trials (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) and using the INR in two trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>). Target intensities varied, with INR ranges of 2.0 to 3.0 (<LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>) and 2.8 to 4.2 (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>) and PTR of 1.2 to 1.5 (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) to 1.3 to 1.8 (<LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>). While conversion of PTRs to INRs cannot be done precisely due to uncertain sensitivity of thromboplastin reagents, the overall target range of INRs in these studies can be estimated as 1.4 to 4.5, with mean achieved INRs between 2.0 and 2.6 (although these estimates must be accepted with caution). In four studies, the control group was assigned placebo and the use of aspirin or other antithrombotic agents was not permitted (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>). In one study (BAATAF) 45% of the control group took aspirin in various doses by participant self selection. In all trials, VKA therapy was managed by study-affiliated investigators. Therapies were administered masked (i.e. double blinded) in two trials (<LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) and open label in the others (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>), in each of which major outcome events were verified by investigators unaware of treatment assignment.</P>
<P>Ischemic stroke was an identified outcome in all trials, with the ischemic nature confirmed by neuroimaging or autopsy in the majority of cases. Stroke required persistence of a focal neurologic deficit for less than 24 hours in four trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>) and for less than 12 hours in one (<LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>). Two trials did not record the occurrence of MI (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>). The primary analysis used an intention-to-treat approach in three trials (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>), whereas a treatment-received (i.e. on-therapy) paradigm was the primary analysis in two (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>), but results using intention-to-treat could be derived from published data and from the Atrial Fibrillation Investigators' database.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-04 11:18:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>There appeared to be minimal differences in the methodological quality of the trials. The method of randomization was described in all and appeared unconfounded. In two studies (<LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) OAC administration was double masked, while in the remaining trials treatment was given open label with events verified by those unaware of treatment assignment.</P>
<P>The fraction of participants lost to follow up ranged from 0% to 3% in three trials: none in two trials (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>); and in one trial, 12 were lost in the control group and 7 in the warfarin group (<LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>). Losses to follow up were not reported in two trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; CAFA). Withdrawal from OAC therapy ranged from a high of 38% during 1.2 years (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>) to a low of 10% during 2.2 years (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>). Considering all trials, about 20% stopped OAC therapy during the mean follow up of 1.5 years.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-04 11:29:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>The five randomized trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; <LINK REF="STD-SPINAF" TYPE="STUDY">SPINAF</LINK>) enrolled 2313 participants with AF and without prior stroke or TIA with a mean follow up of 1.5 years (range 1.2 to 2.3 years).</P>
<SUBSECTION>
<HEADING LEVEL="3">All strokes (including ischemic and hemorrhagic)</HEADING>
<P>Consistent reductions were likewise evident in all trials, with an overall odds ratio (OR) 0.39, 95% confidence interval (CI) 0.26 to 0.59. About 25 strokes would be prevented yearly per 1000 participants given OACs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ischemic strokes</HEADING>
<P>Warfarin therapy was associated with a reduction in ischemic stroke in all five trials, and this effect was statistically significant in four. Pooled results show that ischemic strokes were significantly and substantially reduced by OACs versus control (OR 0.34, 95% CI 0.23 to 0.52). With the annualized rate of ischemic stroke in the control group of about 4% per year, the absolute reduction by OACs was about 2.6% per year for participants without prior stroke or TIA, or about 25 ischemic strokes saved yearly per 1000 participants given warfarin.</P>
<P>Subgroup analysis was performed for the outcome 'ischemic stroke (fatal and non-fatal)'. There was no evidence of a difference in the treatment effect between double blind trials and open label trials (P value 0.92).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">All disabling or fatal strokes (including ischemic and hemorrhagic)</HEADING>
<P>Consistent reductions were seen in all trials, not reaching statistical significance in individual trials, but with a significant reduction in pooled analysis (OR 0.47, 95% CI 0.28 to 0.80). About 12 of these serious stroke events would be prevented yearly for every 1000 participants given warfarin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Myocardial infarction (MI)</HEADING>
<P>Only 15 MIs occurred in three trials (<LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>; SPINAF), too few for a meaningful estimate of the effect of OACs on this outcome (OR 0.87, 95% CI 0.32 to 2.42).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Systemic arterial emboli</HEADING>
<P>Only 10 systemic emboli occurred in the five trials, too few for a meaningful estimate of the effect of OACs, but with the trend similar to that for ischemic stroke (OR 0.45, 95% CI 0.13 to 1.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intracranial hemorrhage</HEADING>
<P>Only seven intracranial hemorrhages occurred, with a non-significant trend toward the expected increase (OR 2.38, 95% CI 0.54 to 10.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Major extracranial bleeding</HEADING>
<P>Major extracranial hemorrhage was similar in those assigned to warfarin, but with wide confidence intervals due to the relatively small number of events (OR 1.07, 95% CI 0.53 to 2.12). Exclusion of the <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK> trial from the analysis (half of the patients in the control group of <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK> received aspirin) resulted in a higher estimated frequency of extracranial hemorrhages in the OAC group (OR 1.52, 95% CI 0.63 to 3.69), but it was not significant.</P>
<P>Considering all randomized data from six trials in which 20% of participants had prior stroke, TIA, or both, major extracranial bleeding was increased in those assigned to OAC (OR 1.80, 95% CI 1.01 to 3.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vascular death</HEADING>
<P>A non-significant trend favouring warfarin was seen (OR 0.84, 95% CI 0.56 to 1.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Stroke, MI or vascular death</HEADING>
<P>Considering this combination of serious vascular events, the odds ratio with OACs was 0.57 (95% CI 0.42 to 0.76). About 25 of these events would be prevented per year for every 1000 participants given warfarin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">All cause mortality </HEADING>
<P>Sixty-nine deaths occurred in the warfarin group among 1225 patients, and 99 in the control group among 1236 patients (OR 0.69, 95% CI 0.50 to 0.94). The mortality rate averaged 5% per year in the control group. About 17 deaths would be prevented per year for every 1000 AF patients given warfarin.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-04 11:25:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Oral anticoagulant (OAC) therapy with adjusted-dose warfarin resulted in statistically significant reductions in all stroke, ischemic stroke, disabling and fatal stroke, all cause mortality, and the combination of stroke, MI or vascular death among participants in these five trials of non-valvular AF without prior stroke or TIA. The relative risk reductions were relatively consistent in all five trials. Considering the rates of these events among the participants assigned to control, the magnitude of absolute reduction by warfarin was moderate: between 12 to 25 prevented yearly per 1000 participants treated. The impressive relative risk reduction in ischemic stroke (by about two thirds) according to intention-to-treat analysis despite a relatively high rate (approximately 20%) of discontinuation of therapy emphasizes the remarkable potential of warfarin therapy to reverse the increased risk of cardioembolic stroke associated with AF.</P>
<P>Four of the trials ended before their planned termination when interim analyses revealed a greater than anticipated efficacy of OAC therapy, while the remaining trial (<LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK>) stopped in response to the publication of the results of three of the trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>; SPAF I). While termination at interim analysis risks overestimating treatment effects, the consistency of results between the four trials suggests that this potential source of bias is minimal.</P>
<P>Intracranial hemorrhage was not significantly increased among participants assigned OACs, but few occurred. The low rates of serious bleeding observed in these trials may reflect patient selection, careful management of anticoagulant therapy by study investigators, and the relatively low target INR ranges. Unexpectedly, there was trend for all-cause mortality to be reduced by more than was vascular death, although confidence intervals widely overlapped. This finding is at odds with other recent clinical trials (<LINK REF="REF-Chimowitz-2005" TYPE="REFERENCE">Chimowitz 2005</LINK>) and probably is due to the play of chance.</P>
<P>The odds ratios conferred by warfarin for primary prevention of major vascular events are similar to those for secondary prevention (<LINK REF="REF-Koudstaal-1995" TYPE="REFERENCE">Koudstaal 1995</LINK>). Hence, it is reasonable to hypothesize that relative risk reductions by OACs are approximately the same for primary and secondary prevention of stroke among patients with nonvalvular AF, although the absolute rate of events is higher for those with prior stroke or TIA and hence the absolute reduction in events is substantially larger.</P>
<P>Several potential caveats pertain to generalizing these results from clinical research to clinical practice. Participants in these trials were, on average, younger than AF patients in the general population (<LINK REF="REF-Feinberg-1995" TYPE="REFERENCE">Feinberg 1995</LINK>; <LINK REF="REF-Go-2001" TYPE="REFERENCE">Go 2001</LINK>). Older AF patients have higher rates of ischemic stroke, but also higher rates of bleeding associated with anticoagulation, so that the risk-benefit equation may not be identical to that characterized in this meta-analysis. Of note, participants in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK> had an age and gender distribution similar to the that of AF patients outside of clinical trials, and the results support the considerable efficacy and modest toxicity of warfarin. On the other hand, the <LINK REF="STD-SPAF-II" TYPE="STUDY">SPAF II</LINK> trial raised concern about the safety of OACs in those over the age of 75 when target INRs extend as high as 4.5. The mean duration of follow up in these five trials averaged only 1.5 years, and hence estimates of efficacy may not be accurate for lifelong OAC therapy required by most AF patients. Finally, warfarin was administered to carefully selected participants using clinical trial protocols; whether the efficacy and safety profiles defined in these circumstances using an agent with a narrow therapeutic window apply directly to clinical practice is an important issue. Observational studies of AF patients given anticoagulants in clinical practice support the generalizability of trial results (<LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>). The striking efficacy of adjusted-dose warfarin, if carefully administered, to suppress stroke in patients with AF is worth emphasis, despite these caveats.</P>
<P>Warfarin anticoagulation is accompanied by occasional serious bleeding, lifestyle changes, the need for close medical monitoring, and expense. Considerable recent attention has focused on stratification of the inherent stroke risk among subgroups of AF patients in order to maximize the absolute benefits of OAC therapy. Risk stratification schemes have been developed using multivariate analysis of participants in clinical trials (<LINK REF="REF-AFI-1994" TYPE="REFERENCE">AFI 1994</LINK>; <LINK REF="REF-Gage-2001" TYPE="REFERENCE">Gage 2001</LINK>; <LINK REF="REF-SPAF-1998" TYPE="REFERENCE">SPAF 1998</LINK>) and population-based cohorts (<LINK REF="REF-Wang-2003" TYPE="REFERENCE">Wang 2003</LINK>). The CHADS 2 scheme has been validated as predictive in a large clinical practice cohort of AF patients (<LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>). The <LINK REF="STD-SPAF-III" TYPE="STUDY">SPAF III</LINK> scheme requires echocardiographic data and has also been validated (<LINK REF="REF-Hart-2004" TYPE="REFERENCE">Hart 2004</LINK>). The inherent risk of stroke should be considered in the decision to use OACs in AF patients, selecting those who stand to benefit most for this therapy (<LINK REF="REF-Hart-1998" TYPE="REFERENCE">Hart 1998</LINK>, <LINK REF="REF-Laupacis-1998" TYPE="REFERENCE">Laupacis 1998</LINK>). For example, among high-risk AF patients with prior stroke or TIA who have stroke rates of about 12% per year, about 70 strokes would be prevented yearly per 1000 AF patients given warfarin, whereas for low-risk AF patients (with a stroke rate of about 2% per year), only 12 strokes would be prevented.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-09-04 11:25:25 +0100" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2008-09-04 11:25:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>Adjusted-dose warfarin prolonging the INR to 2 to 3 substantially reduces stroke, disabling stroke and death for patients with AF and, if administered to selected patients and carefully monitored, hemorrhagic side effects do not offset the benefits. Warfarin anticoagulation has drawbacks including an increased risk of serious bleeding, the need for frequent medical monitoring, restricted use of analgesics, occasional lifestyle changes, and expense. Hence, the decision to use OACs in AF patients, the majority of whom are elderly with other medical problems, is often complex and should consider the inherent risk of stroke, as well as bleeding risk during anticoagulation, access to anticoagulation monitoring, and patient preferences. Selected AF patients at high inherent risk of stroke accrue the greatest absolute benefit from long-term anticoagulation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-09-04 11:25:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>The benefit versus risk of OAC therapy in very elderly AF patients (i.e. over the age of 75) needs to be better defined, particularly when compared with antiplatelet therapies, and administered in a primary care setting.</P>
<P>The extent to which sustained reduction in blood pressure reduces the risk of stroke in AF patients is unknown and may influence optimal antithrombotic prophylaxis. Blood pressure reduction could potentially reduce cardioembolic strokes by altering flow dynamics in the left atrium through ventricular remodeling. It is hypothetically possible that aggressive blood pressure management could obviate the need for anticoagulation in some AF patients, and this warrants further study.</P>
<P>Comparison of vitamin K antagonists (e.g. warfarin) with novel oral anticoagulants that work through other mechanisms (e.g. ximelagatran and others) in AF patients is needed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-09-04 11:25:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>Drs Benavente, Koudstaal, Laupacis, and McBride all contributed to the earlier version of this review. The <LINK REF="STD-BAATAF" TYPE="STUDY">BAATAF</LINK>, <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>, <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK>, and <LINK REF="STD-CAFA" TYPE="STUDY">CAFA</LINK> investigators allowed access to their data in the Atrial Fibrillation Investigators' database to assess unpublished outcomes.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-09-04 11:25:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>Dr. Hart was a principal investigator of the <LINK REF="STD-SPAF-I" TYPE="STUDY">SPAF I</LINK> trial that is included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Drs Aguilar and Hart designed the systematic review, screened and appraised the quality of published papers, abstracted data from included studies, communicated with investigators for unpublished data, interpreted the analyses, and wrote the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-04 11:39:31 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-AFASAK-I" NAME="AFASAK I" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B</AU>
<TI>Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>175-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BAATAF" NAME="BAATAF" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators</AU>
<TI>The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>323</VL>
<PG>1505-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAFA" NAME="CAFA" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, et al</AU>
<TI>Canadian Atrial Fibrillation Anticoagulation (CAFA) Study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPAF-I" NAME="SPAF I" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>The Stroke Prevention in Atrial Fibrillation Study: Final results</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>84</VL>
<PG>527-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPINAF" NAME="SPINAF" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators</AU>
<TI>Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>1406-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-AFASAK-II" NAME="AFASAK II" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al</AU>
<TI>Mini-dose warfarin and aspirin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study (AFASAK 2)</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>1513-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EAFT" NAME="EAFT" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Atrial Fibrillation Trial Study Group</AU>
<TI>Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<PG>1255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harenberg-1993" NAME="Harenberg 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harenberg J, Weuster B, Pfitzei M, Dempfle CE, Stehle G, Kubler W, et al</AU>
<TI>Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1993</YR>
<VL>19 (Suppl)</VL>
<PG>116-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PATAF" NAME="PATAF" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJA, van Ree JW, et al</AU>
<TI>Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1997</YR>
<VL>7 (Suppl 4)</VL>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pengo-1998" NAME="Pengo 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, et al</AU>
<TI>Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>82</VL>
<PG>433-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SAFT" NAME="SAFT" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K</AU>
<TI>Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2003</YR>
<VL>254</VL>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPAF-II" NAME="SPAF II" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>687-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPAF-III" NAME="SPAF III" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomized clinical trial</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<PG>633-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TAFT" NAME="TAFT" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yigit Z</AU>
<TI>The Turkish atrial fibrillation study</TI>
<SO>Turk Kardiyoloji Dernegi Arsivi</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-04 11:39:31 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-04 11:39:31 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-AFI-1994" NAME="AFI 1994" TYPE="JOURNAL_ARTICLE">
<AU>Atrial Fibrillation Investigators</AU>
<TI>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized clinical trials</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>1949-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chimowitz-2005" MODIFIED="2008-09-04 11:25:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chimowitz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al</AU>
<TI>Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>13</NO>
<PG>1305-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2008-09-04 11:25:57 +0100" MODIFIED_BY="Hazel Fraser" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in Health Care. Meta-analysis in Context</SO>
<YR>2001</YR>
<PG>285-312</PG>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feinberg-1995" NAME="Feinberg 1995" TYPE="JOURNAL_ARTICLE">
<AU>Feinberg WM, Blackshear JL, Laupacis A, Kronmal RA, Hart RG</AU>
<TI>Prevalence, age distribution, and gender of patients with atrial fibrillation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<PG>469-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gage-2001" MODIFIED="2008-09-04 11:25:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gage 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ</AU>
<TI>Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>22</NO>
<PG>2864-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Go-2001" NAME="Go 2001" TYPE="JOURNAL_ARTICLE">
<AU>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al</AU>
<TI>Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>18</NO>
<PG>2370-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Go-2003" MODIFIED="2008-09-04 11:39:15 +0100" MODIFIED_BY="Hazel Fraser" NAME="Go 2003" TYPE="JOURNAL_ARTICLE">
<AU>Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al</AU>
<TI>Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>20</NO>
<PG>2685-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-1998" NAME="Hart 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hart RG, Sherman DG, Easton JD, Cairns JA</AU>
<TI>Prevention of stroke in patients with nonvalvular atrial fibrillation</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>674-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-1999" MODIFIED="2008-09-04 11:39:31 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hart RG, Pearce LA, McBride R, Rothbart R, Asinger RW</AU>
<TI>Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-2004" MODIFIED="2008-09-04 11:26:04 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hart 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al</AU>
<TI>Lessons from the Stroke Prevention in Atrial Fibrillation trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>10</NO>
<PG>831-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hylek-2003" NAME="Hylek 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al</AU>
<TI>Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>11</NO>
<PG>1019-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koudstaal-1995" MODIFIED="2008-09-04 11:37:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Koudstaal 1995" TYPE="COCHRANE_REVIEW">
<AU>Koudstaal PJ</AU>
<TI>Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and history of stroke or transient ischemic attacks</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-09-04 11:37:42 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-09-04 11:37:42 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000185. DOI: 10.1002/14651858.CD000185"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1998" MODIFIED="2008-09-04 11:26:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Laupacis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Albers GW, Dalen JE, Dunn MI, Jacobsen AK, Singer DE</AU>
<TI>Antithrombotic therapy in atrial fibrillation</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>114 (5 Suppl)</VL>
<PG>579S-589S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oden-2005" MODIFIED="2008-09-04 11:26:10 +0100" MODIFIED_BY="Hazel Fraser" NAME="Oden 2005" TYPE="OTHER">
<AU>Oden A, Fahlen M, Hart RG</AU>
<TI>Optimal INR for prevention of stroke and death in atrial fibrillation. A critical appraisal</TI>
<SO>Thrombosis Research</SO>
<YR>2005 (in press)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SPAF-1998" NAME="SPAF 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>Prospective identification of patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<PG>1273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Walraven-2002" NAME="van Walraven 2002" TYPE="JOURNAL_ARTICLE">
<AU>van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al</AU>
<TI>Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>19</NO>
<PG>2441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2003" NAME="Wang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al</AU>
<TI>A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>8</NO>
<PG>1049-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolf-1991" NAME="Wolf 1991" TYPE="JOURNAL_ARTICLE">
<AU>Wolf PA, Abbot RD, Kannel WB</AU>
<TI>Atrial fibrillation as an independent risk factor for stroke: the Framingham Study</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>983-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-AFASAK-I">
<CHAR_METHODS>
<P>Computer-generated randomization.<BR/>Randomization to 3 groups (warfarin, aspirin, placebo). <BR/>Primary stroke prevention trial.<BR/>Double-blind: aspirin vs placebo.<BR/>Open-label: warfarin.<BR/>On therapy analysis.<BR/>Exclusions during the trial: none.<BR/>Losses to follow up: not reported.<BR/>Off therapy: 222 patients in the three groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Denmark.<BR/>Total number of patients: 1,007; 315 assigned to warfarin and 315 assigned to placebo included in these analyses.<BR/>Inclusion criteria: Chronic non-rheumatic AF (verified by ECG).<BR/>Those with intermittent AF were not included.<BR/>No stroke or TIA within the month before randomization and no prior anticoagulation therapy during prior 6 months.<BR/>Older than 18 years.<BR/>Age: range 38 to 91, median 74.2.<BR/>54% were male.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: adjusted-dose of VKA (warfarin) (335 patients), with a target INR range of 2.8 to 4.2.<BR/>Mean achieved INR was estimated as about 2.5. Within target range, 73% of the time, above target range 0.6% and below in 26% of the time. 38% had been withdrawn from OAC and 15% from placebo.<BR/>Aspirin dose: 75 mg/day.<BR/>The trial was stopped at an interim analysis after a mean follow up of 1.2 years per participant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: ischemic stroke; TIA; systemic emboli (extremities and viscera).<BR/>Secondary outcome: death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>About 6% of the participants had prior stroke, TIA or both.<BR/>Major or minor bleeding was not predefined, only one patient required transfusion.<BR/>Myocardial infarction was not reported.<BR/>The main report presented only on-therapy results and included hemorrhagic stroke in the primary analysis. Intent-to-treat results for stroke were later reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-BAATAF">
<CHAR_METHODS>
<P>Computer generated randomization. Randomization was blocked according to three factors: site of recruitment; whether AF was sustained or intermittent; and duration of AF (less than 1 year or more than 1 year).<BR/>Intention-to-treat analysis.<BR/>Exclusions during the trial: 8.<BR/>Losses to follow up: none.<BR/>Off therapy: 21 in the treatment group.<BR/>Randomized to two groups (warfarin vs placebo). Open label.<BR/>Primary stroke prevention trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA.<BR/>Total number of patients: 420; 205 assigned to warfarin and 201 assigned to control included in these analyses.<BR/>Inclusion criteria: chronic sustained or intermittent nonvalvular AF; intermittent AF documented by ECG within 18 months prior to entry; chronic AF documented by two separated ECG and normal thyroid function.<BR/>Exclusion criteria: no stroke within previous 6 months; no TIA for which the patient was being treated; no mitral stenosis, prosthetic heart valves, intracardiac thrombus, left ventricular aneurysm, severe congestive heart failure, transient AF, cardioversion planned, definitive indication or contraindication for OAC; and no neurological condition predisposing to intracranial hemorrhage.<BR/>Age: mean 68 years.<BR/>75% male.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: warfarin (212 patients) with a target prothrombin ratio of 1.3 to 1.5 (estimated INR equivalent 1.5 to 2.7). The control group (208 patients, mean age 67.5 years) was allowed to take aspirin, and aspirin in various doses was self-selected for 46% of follow up.<BR/>Prothrombin-time ratio: within target range during 83% of time, 8% were lower and 9% higher.<BR/>About 10% of patients were withdrawn from OAC, the mean achieved (estimated) INR was about 2.1.<BR/>Follow up: average 2.2 years per participant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: ischemic stroke.<BR/>Secondary outcome: systemic emboli (viscera and extremities); intracranial bleeding; extracranial bleeding (major and minor); and death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>About 3% of the participants had prior stroke, TIA, or both.<BR/>The trial was terminated early at an interim analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CAFA">
<CHAR_METHODS>
<P>Randomization by sequential use of packages with warfarin or placebo according to a predetermined random order.<BR/>Randomized to 2 groups: warfarin vs placebo.<BR/>Primary stroke prevention trial.<BR/>Exclusions: 2 patients on warfarin and 3 on placebo.<BR/>Losses to follow up were not reported.<BR/>Off therapy: 49 in warfarin group and 43 in placebo group.<BR/>Triple blinded (patient, co-ordinating center, and investigators).<BR/>Efficacy analysis was used for primary analysis and intention to treat for secondary analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Canada.<BR/>Total number of patients: 378; 181 assigned to warfarin and 184 assigned to placebo included in these analyses.<BR/>Inclusion criteria: chronic nonvalvular AF present for more than 1 month or paroxysmal AF documented at least 3 times during the previous 3 months (documented by ECG) and 19 years old or more.<BR/>Exclusion criteria: stroke or TIA within 1 year of entry in the trial; mitral stenosis; prosthetic heart valve; MI within 1 month; uncontrolled hypertension; requirement for OAC; contraindication for OAC; requirement for antiplatelet drug therapy; and hyperthyroidism.<BR/>Age: mean 67 years.<BR/>75% males.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: warfarin (187 patients, mean age 68 years), adjusted dose with a target INR range of 2.0 to 3.0. The mean achieved INR was 2.4.<BR/>Control: 191 patients, mean age 67.4 years.<BR/>INR was within target range 43% of the time, below 39% of the time and above 17% of time.<BR/>Follow up: mean 1.3 years.<BR/>About 26% had been withdrawn from OAC and 23% from the control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: ischemic stroke (non lacunar); systemic emboli (viscera or extremity); intracranial or systemic fatal hemorrhage.<BR/>Secondary outcomes: TIA, lacunar infarction; major and minor bleeding; and death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>4% of participants had prior stroke or TIA.<BR/>The trial was terminated when the results of AFASAK, SPAF I, and BAATAF were known, without analysis of interim results, with a mean follow up of 1.3 years per participant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SPAF-I">
<CHAR_METHODS>
<P>Randomized<BR/>primary stroke prevention trial. <BR/>Randomized to 2 groups: Group I = anticoagulation eligible (warfarin, aspirin, placebo) vs Group II = ineligible (aspirin, placebo), with age greater than 75 years precluding participation in Group I (this restriction was suspended during the last month of recruitment). <BR/>Open label: warfarin vs aspirin vs placebo.<BR/>Double blind: aspirin vs placebo.<BR/>Intention-to-treat analysis.<BR/>Exclusions: none<BR/>Losses to follow up: none.<BR/>Off therapy: 11% warfarin, 5% aspirin and 7% placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA.<BR/>Total number of patients: 1330; only Group I patients considered in these analyses because Group II patients were not randomized to OAC (193 assigned warfarin and 194 assigned placebo are included in these analyses).<BR/>Inclusion criteria: nonvalvular chronic AF documented by ECG within 1 year (constant or intermittent).<BR/>Exclusion criteria: history of stroke or TIA within previous 2 years; mitral stenosis; prosthetic heart valves; transient lone AF; congestive heart failure; coronary bypass surgery or unstable angina within the year prior to randomization; PTCA within 3 months; requirement for warfarin or NSAIDs; carotid endarterectomy within 1 year; life expectancy less than 1 year; and unable to obtain consent or follow up.<BR/>Age: mean 67 years.<BR/>71% male.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group I participants were assigned to receive adjusted-dose warfarin (not masked, n=210) with a target prothrombin time ratio of 1.3 to 1.8 (approximate INR equivalent of 2.0 to 4.5) vs aspirin 325 mg/day enteric-coated (double-masked, n=206) vs placebo (n=211).<BR/>Mean achieved (estimated) INR was about 2.6. 11% had been withdrawn from warfarin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: ischemic stroke and systemic embolism.<BR/>Secondary outcomes: TIA; myocardial infarction; intracerebral hemorrhage; death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>About 8% of Group I participants had prior stroke, TIA, or both.<BR/>The trial was stopped early after an interim analysis due to the effect of aspirin vs placebo in Group I (i.e. not because of warfarin effects).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SPINAF">
<CHAR_METHODS>
<P>Randomly assigned according to list generated by the Co-ordinating Center.<BR/>Primary and secondary stroke prevention trial.<BR/>Randomized to two groups (warfarin vs placebo).<BR/>Double-blinded,<BR/>Intention-to-treat analysis.<BR/>Losses to follow up: 12 in control group and 7 in warfarin group.<BR/>Exclusions: 4 in control group and 9 in warfarin group (in primary prevention group).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA.<BR/>Total number of patients: 571.<BR/>Only men were included without intermittent AF. 525 participants without prior stroke and 46 with prior ischemic stroke were randomized separately.<BR/>Inclusion criteria (for primary prevention): chronic nonvalvular AF (documented by ECG at least 4 weeks apart); baseline prothrombin-time within normal range.<BR/>Inclusion criteria (secondary prevention): clinical evidence of stroke at least one month before entry.<BR/>Exclusion criteria: clinical evidence of stroke (for primary prevention); intermittent AF; rheumatic heart disease; indication for OAC or antiplatelet agent including prosthetic heart valve, mitral stenosis, active thromboembolic disease, coronary artery bypass surgery, MI within one month prior to entry in the trial; contraindication to anticoagulation; OAC within 6 months for more than 1 continuous month; TIA within 5 years; cardioversion planned; or hyperthyroidism.<BR/>Age: mean 67 years.<BR/>100% men.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients without prior stroke (n=525) were randomized to receive adjusted-dose warfarin (n=260) with a target prothrombin time ratio of 1.2 to 1.5 (estimated INR equivalent of 1.4 to 2.8) vs placebo (n=265).<BR/>A separate Arm II included 46 additional participants with prior ischemic stroke randomized to the same treatments.<BR/>Mean achieved (estimated) INR was about 2.0. <BR/>30% had been withdrawn from warfarin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: ischemic stroke.<BR/>Secondary outcome: cerebral hemorrhage and death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The trial was stopped at an interim analysis after a mean follow up of 1.7% years per participant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AF: atrial fibrillation<BR/>ECG: electrocardiogram<BR/>INR: International Normalized Ratio<BR/>MI: myocardial infarction<BR/>NSAID: non-steroidal anti-inflammatory drug<BR/>OAC: oral anticoagulant<BR/>PTCA: percutaneous transluminal coronary angioplasty <BR/>TIA: transient ischemic attack<BR/>VKA: vitamin K antagonist<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-AFASAK-II">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients randomized to adjusted dose of warfarin or a fixed dose of warfarin plus aspirin; no placebo or control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-EAFT">
<CHAR_REASON_FOR_EXCLUSION>
<P>Secondary prevention study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harenberg-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Secondary prevention study of parenteral heparin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-PATAF">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo or control arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pengo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients randomized to two different regimens of warfarin; no placebo or control arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SAFT">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were randomized to receive aspirin plus low, fixed-dose warfarin vs control. The mean INR was not prolonged beyond the normal range.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SPAF-II">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were allocated to receive warfarin or aspirin (no placebo or control).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SPAF-III">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were allocated to adjusted-dose warfarin or a fixed dose of warfarin plus aspirin (no placebo or control).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TAFT">
<CHAR_REASON_FOR_EXCLUSION>
<P>51% of randomized patients were excluded from the published results due to ill-defined poor compliance. The results have such potential for bias that they were not considered.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>INR: International Normalized Ratio<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-AFASAK-I">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-BAATAF">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-CAFA">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SPAF-I">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SPINAF">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Sensitivity analysis: double-blind trials (DBT) versus open-label trials (OLT)</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>n on VKA</P>
</TH>
<TH>
<P>N on VKA</P>
</TH>
<TH>
<P>n on control</P>
</TH>
<TH>
<P>N on control</P>
</TH>
</TR>
<TR>
<TD>
<P>CAFA</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>181</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>184</P>
</TD>
</TR>
<TR>
<TD>
<P>SPINAF</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>260</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>265</P>
</TD>
</TR>
<TR>
<TD>
<P>Total DBT</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>441</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>449</P>
</TD>
</TR>
<TR>
<TD>
<P>AFASAK I</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>315</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>315</P>
</TD>
</TR>
<TR>
<TD>
<P>BAATAF</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>205</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
<TR>
<TD>
<P>SPAF I</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>193</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>194</P>
</TD>
</TR>
<TR>
<TD>
<P>Total OLT</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>713</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>710</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Anticoagulants versus control</NAME>
<DICH_OUTCOME CHI2="1.850166670220957" CI_END="0.5905133105311762" CI_START="0.2629606430501169" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.39405806661827325" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.228770308676901" LOG_CI_START="-0.5801092468912332" LOG_EFFECT_SIZE="-0.40443977778406703" METHOD="PETO" NO="1" P_CHI2="0.7632924697201926" P_Q="1.0" P_Z="6.410420555605177E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="4.512379996370229">
<NAME>All ischemic stroke or intracranial hemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8528701752139752" CI_START="0.16150300256426642" EFFECT_SIZE="0.3711348731857046" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.06911707255961037" LOG_CI_START="-0.7918193991225326" LOG_EFFECT_SIZE="-0.4304682358410714" ORDER="56557" O_E="-5.5" SE="0.4245189240572731" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="5.548887122416534" WEIGHT="23.633805838714782"/>
<DICH_DATA CI_END="0.8725755532315604" CI_START="0.10370976606067846" EFFECT_SIZE="0.3008232146891463" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.05919695871724907" LOG_CI_START="-0.9841803453799232" LOG_EFFECT_SIZE="-0.5216886520485862" ORDER="56558" O_E="-4.068965517241379" SE="0.5433398200672638" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="3.387325494340952" WEIGHT="14.427288081311445"/>
<DICH_DATA CI_END="1.8837581598206539" CI_START="0.23903843566384028" EFFECT_SIZE="0.6710369614950606" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.27502514654758964" LOG_CI_START="-0.6215322620031869" LOG_EFFECT_SIZE="-0.17325355772779863" ORDER="56559" O_E="-1.4383561643835616" SE="0.5266422598134741" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="3.605525643431442" WEIGHT="15.356645598199883"/>
<DICH_DATA CI_END="1.1005214234991276" CI_START="0.19728708407274237" EFFECT_SIZE="0.46595993669169294" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.04159850124365442" LOG_CI_START="-0.7049013460683718" LOG_EFFECT_SIZE="-0.33165142241235873" ORDER="56560" O_E="-3.9715762273901802" SE="0.4384977055449244" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="5.200742476747524" WEIGHT="22.15098905437438"/>
<DICH_DATA CI_END="0.6824518491269436" CI_START="0.13281969276302932" EFFECT_SIZE="0.30106983396979825" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.16592798516071303" LOG_CI_START="-0.8767375287009642" LOG_EFFECT_SIZE="-0.5213327569308386" ORDER="56561" O_E="-6.885714285714286" SE="0.41753304443953076" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="5.736120891104534" WEIGHT="24.431271427399512"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8062273664340573" CI_END="0.522574844802754" CI_START="0.22607816551152096" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3437190164298077" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.28185149974894136" LOG_CI_START="-0.6457413795200033" LOG_EFFECT_SIZE="-0.46379643963447237" METHOD="PETO" NO="2" P_CHI2="0.7713428663455004" P_Q="1.0" P_Z="5.84859977073691E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="4.996150584970243">
<NAME>All ischemic stroke (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8528701752139752" CI_START="0.16150300256426642" EFFECT_SIZE="0.3711348731857046" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.06911707255961037" LOG_CI_START="-0.7918193991225326" LOG_EFFECT_SIZE="-0.4304682358410714" ORDER="56562" O_E="-5.5" SE="0.4245189240572731" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="5.548887122416534" WEIGHT="25.352515057236637"/>
<DICH_DATA CI_END="0.7091978228244836" CI_START="0.07799895685768725" EFFECT_SIZE="0.2351950050193512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.14923260631528823" LOG_CI_START="-1.1079112054374636" LOG_EFFECT_SIZE="-0.6285719058763758" ORDER="56563" O_E="-4.564039408866995" SE="0.5631325546599664" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="3.153397585748529" WEIGHT="14.407674549942294"/>
<DICH_DATA CI_END="1.6344739466344504" CI_START="0.19349771191520782" EFFECT_SIZE="0.5623761809134395" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21337800235715168" LOG_CI_START="-0.7133241660893828" LOG_EFFECT_SIZE="-0.2499730818661155" ORDER="56564" O_E="-1.9424657534246572" SE="0.5443494409952103" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="3.37477200225183" WEIGHT="15.419120287415275"/>
<DICH_DATA CI_END="1.0207543771378955" CI_START="0.15421261598131364" EFFECT_SIZE="0.3967533273619911" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.008921250914661229" LOG_CI_START="-0.8118800956304294" LOG_EFFECT_SIZE="-0.4014794223578841" ORDER="56565" O_E="-3.9767441860465116" SE="0.4821427739927794" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="4.30178474851271" WEIGHT="19.654583018831246"/>
<DICH_DATA CI_END="0.6025213500400174" CI_START="0.1133961961446457" EFFECT_SIZE="0.261387890290416" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.22002755947460753" LOG_CI_START="-0.9454015135303956" LOG_EFFECT_SIZE="-0.5827145365025016" ORDER="56566" O_E="-7.390476190476191" SE="0.42608825127135186" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="5.508088141108861" WEIGHT="25.16610708657454"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5988482947755569" CI_END="0.7990798578706209" CI_START="0.27947734787906664" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.47257244885970934" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.0974098163061771" LOG_CI_START="-0.5536533866677007" LOG_EFFECT_SIZE="-0.32553160148693894" METHOD="PETO" NO="3" P_CHI2="0.9631916144609782" P_Q="1.0" P_Z="0.005159802434437859" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="2.796884191654366">
<NAME>All disabling or fatal ischemic stroke or intracranial hemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0714323038295466" CI_START="0.13832403775155971" EFFECT_SIZE="0.3849738204646633" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.029964736271879313" LOG_CI_START="-0.8591023422642989" LOG_EFFECT_SIZE="-0.4145688029962098" ORDER="56567" O_E="-3.5" SE="0.5222424028851675" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="3.666534181240064" WEIGHT="26.334462369963827"/>
<DICH_DATA CI_END="1.5147381117406087" CI_START="0.12343093828815793" EFFECT_SIZE="0.4323951276240008" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.18033755266834384" LOG_CI_START="-0.9085759696077981" LOG_EFFECT_SIZE="-0.3641192084697271" ORDER="56568" O_E="-2.0492610837438425" SE="0.6396331931938732" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="2.4442071715725526" WEIGHT="17.55523843566174"/>
<DICH_DATA CI_END="3.387867073657696" CI_START="0.1707055044206589" EFFECT_SIZE="0.7604785057573149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5299263620159661" LOG_CI_START="-0.767752474778786" LOG_EFFECT_SIZE="-0.11891305638141" ORDER="56569" O_E="-0.4712328767123286" SE="0.7622629723470783" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="1.7210375737979418" WEIGHT="12.36115551748303"/>
<DICH_DATA CI_END="1.5534696407127497" CI_START="0.12642381593123783" EFFECT_SIZE="0.4431653866359994" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19130277030437484" LOG_CI_START="-0.8981711052211265" LOG_EFFECT_SIZE="-0.35343416745837586" ORDER="56570" O_E="-1.9870801033591734" SE="0.6399623474663403" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="2.4416935413870693" WEIGHT="17.53718457436943"/>
<DICH_DATA CI_END="1.4340580220683554" CI_START="0.1842572183581193" EFFECT_SIZE="0.5140384636488418" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.15656672326646667" LOG_CI_START="-0.7345754894570065" LOG_EFFECT_SIZE="-0.2890043830952699" ORDER="56571" O_E="-2.428571428571429" SE="0.5234613469788645" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="3.6494781118554296" WEIGHT="26.211959102521977"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3251862833762567" CI_END="2.416312011967652" CI_START="0.3160633189025503" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8739036525879698" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="13.985386276409393" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3831530128657982" LOG_CI_START="-0.5002259037889786" LOG_EFFECT_SIZE="-0.0585364454615902" METHOD="PETO" NO="4" P_CHI2="0.3126743653376286" P_Q="1.0" P_Z="0.7950557693608009" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="658" TOTAL_2="660" WEIGHT="99.99999999999999" Z="0.2597511050460035">
<NAME>Myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.635611217108828" CI_START="0.3847197867710865" EFFECT_SIZE="1.9253597827043125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.98387926852944" LOG_CI_START="-0.41485547663960937" LOG_EFFECT_SIZE="0.28451189594491527" ORDER="56572" O_E="0.9704433497536944" SE="0.8216237131609545" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="1.4813376797409412" WEIGHT="39.886261624945"/>
<DICH_DATA CI_END="7.191071256403115" CI_START="0.14051750515392286" EFFECT_SIZE="1.0052220612053095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8567935922033718" LOG_CI_START="-0.8522695695795781" LOG_EFFECT_SIZE="0.00226201131189677" ORDER="56573" O_E="0.0051679586563306845" SE="1.0039121612303967" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="0.9922213542188304" WEIGHT="26.716393611989005"/>
<DICH_DATA CI_END="1.7677541156796563" CI_START="0.05233975624594246" EFFECT_SIZE="0.30417728303973457" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24742185704026837" LOG_CI_START="-1.281168304265657" LOG_EFFECT_SIZE="-0.5168732236126943" ORDER="56574" O_E="-1.4761904761904763" SE="0.8979014273944322" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="1.240345502068512" WEIGHT="33.39734476306598"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.111591965772191" CI_END="1.5693243895631588" CI_START="0.13092811336452886" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4532865336433957" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="3.586330309362962" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.19571272436182222" LOG_CI_START="-0.8829670901325388" LOG_EFFECT_SIZE="-0.3436271828853583" METHOD="PETO" NO="5" P_CHI2="0.37473813207532036" P_Q="1.0" P_Z="0.21175913334059238" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="99.99999999999999" Z="1.248742942093465">
<NAME>All systemic emboli</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.161557249373658" CI_START="0.00841955470538119" EFFECT_SIZE="0.13490496473412242" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3347667424178161" LOG_CI_START="-2.0747108769219267" LOG_EFFECT_SIZE="-0.8699720672520552" ORDER="56575" O_E="-1.0" SE="1.4153390807067385" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="0.4992050874403816" WEIGHT="20.04191935297591"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="56576" O_E="0.0" SE="0.0" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.031038714578304" CI_START="0.053752974474736565" EFFECT_SIZE="0.5200320140204246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7016576592981264" LOG_CI_START="-1.2695974986268217" LOG_EFFECT_SIZE="-0.28396991966434754" ORDER="56577" O_E="-0.4876712328767123" SE="1.157925037635519" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="0.7458287330983897" WEIGHT="29.943283223601544"/>
<DICH_DATA CI_END="2.171433509144474" CI_START="0.008434362806624584" EFFECT_SIZE="0.13533165936537708" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.33674653549251055" LOG_CI_START="-2.0739477216130506" LOG_EFFECT_SIZE="-0.86860059306027" ORDER="56578" O_E="-0.9974160206718347" SE="1.4160537397528343" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="0.49870133338674894" WEIGHT="20.021694803245442"/>
<DICH_DATA CI_END="19.221120993049027" CI_START="0.20613958170137814" EFFECT_SIZE="1.9905360688364089" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2837787125155995" LOG_CI_START="-0.6858386095598689" LOG_EFFECT_SIZE="0.2989700514778654" ORDER="56579" O_E="0.5142857142857142" SE="1.1569629647501167" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="0.7470696370151114" WEIGHT="29.9931026201771"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.709077158328445" CI_END="10.497708093515332" CI_START="0.5386484768704232" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.3779349182015785" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.0210944923092335" LOG_CI_START="-0.26869456386559676" LOG_EFFECT_SIZE="0.37619996422181845" METHOD="PETO" NO="6" P_CHI2="0.6349177164513706" P_Q="1.0" P_Z="0.25289446650915837" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="99.99999999999999" Z="1.143347243225601">
<NAME>All intracranial hemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="56580" O_E="0.0" SE="0.0" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="365.25876003648233" CI_START="0.14375706908649863" EFFECT_SIZE="7.246276892378141" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.562600640458173" LOG_CI_START="-0.8423707901877318" LOG_EFFECT_SIZE="0.8601149251352207" ORDER="56581" O_E="0.49507389162561577" SE="2.000097073241818" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="0.24997573345628382" WEIGHT="14.348629795245058"/>
<DICH_DATA CI_END="378.65858447623503" CI_START="0.14904816126441256" EFFECT_SIZE="7.512547222025835" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5782478070563086" LOG_CI_START="-0.8266733772807632" LOG_EFFECT_SIZE="0.8757872148877729" ORDER="56582" O_E="0.5041095890410958" SE="2.0000675583112866" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="0.2499831112779133" WEIGHT="14.34905328287641"/>
<DICH_DATA CI_END="7.191071256403115" CI_START="0.14051750515392286" EFFECT_SIZE="1.0052220612053095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8567935922033718" LOG_CI_START="-0.8522695695795781" LOG_EFFECT_SIZE="0.00226201131189677" ORDER="56583" O_E="0.0051679586563306845" SE="1.0039121612303967" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="0.9922213542188304" WEIGHT="56.95359581418131"/>
<DICH_DATA CI_END="379.68293578402336" CI_START="0.14943780594501696" EFFECT_SIZE="7.5325284518763835" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.579421078937613" LOG_CI_START="-0.82553951740525" LOG_EFFECT_SIZE="0.8769407807661815" ORDER="56584" O_E="0.5047619047619047" SE="2.000090709118581" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="0.24997732426303856" WEIGHT="14.348721107697207"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8996128559092909" CI_END="2.1232853982573525" CI_START="0.5347736589573544" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0655876789062493" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.32700837313814723" LOG_CI_START="-0.27182999268007013" LOG_EFFECT_SIZE="0.027589190229038538" METHOD="PETO" NO="7" P_CHI2="0.5935017461252969" P_Q="1.0" P_Z="0.8566849253929204" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="0.1805957076168847">
<NAME>All major extracranial bleeds</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="56585" O_E="0.0" SE="0.0" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.836265790270664" CI_START="0.20195608551665717" EFFECT_SIZE="0.6089704844827986" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.26393554336492003" LOG_CI_START="-0.6947430557572554" LOG_EFFECT_SIZE="-0.21540375619616756" ORDER="56586" O_E="-1.5640394088669947" SE="0.5631325546599664" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="3.153397585748529" WEIGHT="39.018733434349535"/>
<DICH_DATA CI_END="10.015458807071974" CI_START="0.3989982877689926" EFFECT_SIZE="1.9990374972077423" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.000670849067994" LOG_CI_START="-0.3990289680076723" LOG_EFFECT_SIZE="0.3008209405301609" ORDER="56587" O_E="1.0246575342465754" SE="0.8221906011760844" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="1.4792956639907289" WEIGHT="18.304143900123577"/>
<DICH_DATA CI_END="7.191071256403115" CI_START="0.14051750515392286" EFFECT_SIZE="1.0052220612053095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8567935922033718" LOG_CI_START="-0.8522695695795781" LOG_EFFECT_SIZE="0.00226201131189677" ORDER="56588" O_E="0.0051679586563306845" SE="1.0039121612303967" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="0.9922213542188304" WEIGHT="12.277303915974153"/>
<DICH_DATA CI_END="5.348631264252413" CI_START="0.4386638951271871" EFFECT_SIZE="1.531747833024749" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.728242658575449" LOG_CI_START="-0.3578681093659768" LOG_EFFECT_SIZE="0.18518727460473602" ORDER="56589" O_E="1.0476190476190474" SE="0.6379868414238031" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="2.4568382060203215" WEIGHT="30.399818749552736"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.34514918478612" CI_END="1.2699676258890578" CI_START="0.5563618838521931" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8405721746351906" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="51" I2="25.16579310105719" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.10379265002922836" LOG_CI_START="-0.25464263101588736" LOG_EFFECT_SIZE="-0.0754249904933295" METHOD="PETO" NO="8" P_CHI2="0.25368015944043054" P_Q="1.0" P_Z="0.40944854507676287" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="0.8248644746698061">
<NAME>All vascular death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6957752782249391" CI_START="0.38242935122211563" EFFECT_SIZE="0.8053038181146703" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.229368299634615" LOG_CI_START="-0.4174487832771501" LOG_EFFECT_SIZE="-0.09404024182126759" ORDER="56590" O_E="-1.5" SE="0.37994355629856913" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="6.927265500794912" WEIGHT="30.708495471480415"/>
<DICH_DATA CI_END="1.1367829537342875" CI_START="0.18053591991429765" EFFECT_SIZE="0.4530233507175012" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.05567755264404289" LOG_CI_START="-0.7434363767579035" LOG_EFFECT_SIZE="-0.3438794120569303" ORDER="56591" O_E="-3.5935960591133007" SE="0.4694034778084502" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="4.538448316306308" WEIGHT="20.11889389151425"/>
<DICH_DATA CI_END="4.9525916786886715" CI_START="0.542644287216877" EFFECT_SIZE="1.639358283401847" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6948325236209992" LOG_CI_START="-0.2654847647413587" LOG_EFFECT_SIZE="0.2146738794398203" ORDER="56592" O_E="1.5534246575342463" SE="0.5640951288312922" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="3.142644827493767" WEIGHT="13.931311632633328"/>
<DICH_DATA CI_END="1.5534696407127497" CI_START="0.12642381593123783" EFFECT_SIZE="0.4431653866359994" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19130277030437484" LOG_CI_START="-0.8981711052211265" LOG_EFFECT_SIZE="-0.35343416745837586" ORDER="56593" O_E="-1.9870801033591734" SE="0.6399623474663403" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="2.4416935413870693" WEIGHT="10.824001916748198"/>
<DICH_DATA CI_END="3.0873978066612233" CI_START="0.5810568658479116" EFFECT_SIZE="1.3393855655352893" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.48959259129196975" LOG_CI_START="-0.2357813627638183" LOG_EFFECT_SIZE="0.1269056142640757" ORDER="56594" O_E="1.6095238095238091" SE="0.42608825127135186" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="5.508088141108861" WEIGHT="24.4172970876238"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1454590776320637" CI_END="0.7662969562248305" CI_START="0.4215245255610106" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5683422920314115" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.11560289948231355" LOG_CI_START="-0.37517715174874366" LOG_EFFECT_SIZE="-0.24539002561552858" METHOD="PETO" NO="9" P_CHI2="0.7090261392416853" P_Q="1.0" P_Z="2.1078553637013766E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="3.705726651795486">
<NAME>Composite outcome: stroke (ischemic or hemorrhagic), MI or vascular death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0489786247785076" CI_START="0.3234945648733638" EFFECT_SIZE="0.5825280111584188" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="0.020766638588862837" LOG_CI_START="-0.4901330116423772" LOG_EFFECT_SIZE="-0.2346831865267572" ORDER="56595" O_E="-6.0" SE="0.3001049835398862" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="11.103338632750399" WEIGHT="25.81380426052809"/>
<DICH_DATA CI_END="0.9344339844391869" CI_START="0.23813256598556845" EFFECT_SIZE="0.4717193683310262" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.02945137508396976" LOG_CI_START="-0.6231812082880956" LOG_EFFECT_SIZE="-0.3263162916860327" ORDER="56596" O_E="-6.177339901477833" SE="0.3487598430341777" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="8.221424122562224" WEIGHT="19.11373146961607"/>
<DICH_DATA CI_END="2.1025656625644276" CI_START="0.4150882071791946" EFFECT_SIZE="0.9342110100777038" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.3227495675824856" LOG_CI_START="-0.38185960492491083" LOG_EFFECT_SIZE="-0.02955501867121266" ORDER="56597" O_E="-0.3972602739726021" SE="0.41389091580250026" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="5.837517708412811" WEIGHT="13.571462104908159"/>
<DICH_DATA CI_END="0.9450262847901096" CI_START="0.20841326885333905" EFFECT_SIZE="0.4437972703447299" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.024556111934600503" LOG_CI_START="-0.6810746346702976" LOG_EFFECT_SIZE="-0.35281537330244905" ORDER="56598" O_E="-5.462532299741602" SE="0.3856422300740484" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="6.724048367819776" WEIGHT="15.63252947120351"/>
<DICH_DATA CI_END="1.024670450236112" CI_START="0.3163914182833788" EFFECT_SIZE="0.5693829440923497" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="31" LOG_CI_END="0.010584212068297717" LOG_CI_START="-0.49977530470254805" LOG_EFFECT_SIZE="-0.24459554631712516" ORDER="56599" O_E="-6.266666666666666" SE="0.2997877064715468" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="11.12685326547922" WEIGHT="25.868472693744167"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.272103704994311" CI_END="0.9402674186213867" CI_START="0.5016517934535586" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6867946104020959" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="99" I2="6.369314131494701" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.02674861244841841" LOG_CI_START="-0.29959763077013596" LOG_EFFECT_SIZE="-0.16317312160927716" METHOD="PETO" NO="10" P_CHI2="0.37043138752858007" P_Q="1.0" P_Z="0.01906528004531648" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1225" TOTAL_2="1236" WEIGHT="100.0" Z="2.3442520963888107">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2604538283643512" CI_START="0.3898382458709861" EFFECT_SIZE="0.7009801063160976" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="28" LOG_CI_END="0.10052694167938905" LOG_CI_START="-0.4091155557881234" LOG_EFFECT_SIZE="-0.15429430705436722" ORDER="56600" O_E="-3.9642324888226526" SE="0.29936652578346606" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="11.15818417247652" WEIGHT="28.66246389125565"/>
<DICH_DATA CI_END="0.7914616563958377" CI_START="0.20556100274002817" EFFECT_SIZE="0.40335301129285256" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="26" LOG_CI_END="-0.10157012037089086" LOG_CI_START="-0.6870592724647843" LOG_EFFECT_SIZE="-0.3943146964178375" ORDER="56601" O_E="-7.676190476190477" SE="0.34391922615799764" STUDY_ID="STD-BAATAF" TOTAL_1="212" TOTAL_2="208" VAR="8.454483680504818" WEIGHT="21.71736274163828"/>
<DICH_DATA CI_END="3.3216457641924464" CI_START="0.5012529985523115" EFFECT_SIZE="1.290342938691125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5213533153942826" LOG_CI_START="-0.29994301636512294" LOG_EFFECT_SIZE="0.11070514951457987" ORDER="56602" O_E="1.095238095238095" SE="0.48243353075788425" STUDY_ID="STD-CAFA" TOTAL_1="187" TOTAL_2="191" VAR="4.296601045369518" WEIGHT="11.036847072466104"/>
<DICH_DATA CI_END="2.1690908943550165" CI_START="0.25815700488834037" EFFECT_SIZE="0.748308765562226" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3362777512256837" LOG_CI_START="-0.5881160862159118" LOG_EFFECT_SIZE="-0.1259191674951141" ORDER="56603" O_E="-0.9833729216152021" SE="0.5429935159364865" STUDY_ID="STD-SPAF-I" TOTAL_1="210" TOTAL_2="211" VAR="3.391647530763198" WEIGHT="8.71225760210682"/>
<DICH_DATA CI_END="1.361161707612872" CI_START="0.4312051411674218" EFFECT_SIZE="0.7661200469136005" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.13390972296392195" LOG_CI_START="-0.36531606978947334" LOG_EFFECT_SIZE="-0.11570317341277568" ORDER="56604" O_E="-3.0980735551663763" SE="0.2932477018708736" STUDY_ID="STD-SPINAF" TOTAL_1="281" TOTAL_2="290" VAR="11.628689255904044" WEIGHT="29.871068692533143"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Subgroup analysis</NAME>
<DICH_OUTCOME CHI2="1.8062273664340573" CI_END="0.522574844802754" CI_START="0.22607816551152096" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3437190164298077" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.28185149974894136" LOG_CI_START="-0.6457413795200033" LOG_EFFECT_SIZE="-0.46379643963447237" METHOD="PETO" NO="1" P_CHI2="0.7713428663455004" P_Q="0.9467839007838543" P_Z="5.84859977073691E-7" Q="0.004455030610893251" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1154" TOTAL_2="1159" WEIGHT="100.0" Z="4.996150584970243">
<NAME>Ischemic stroke (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.228394019775397" CI_END="0.6749925561651045" CI_START="0.18117651185035683" DF="1.0" EFFECT_SIZE="0.3497038702258665" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="28" I2="18.592895772738885" ID="CMP-002.01.01" LOG_CI_END="-0.17070101655304182" LOG_CI_START="-0.7418981059692374" LOG_EFFECT_SIZE="-0.45629956126113963" NO="1" P_CHI2="0.26771966739217135" P_Z="0.0017395962485702889" STUDIES="2" TAU2="0.0" TOTAL_1="441" TOTAL_2="449" WEIGHT="40.58522737398982" Z="3.131425992199407">
<NAME>Double blind trials</NAME>
<DICH_DATA CI_END="1.6344739466344504" CI_START="0.19349771191520782" EFFECT_SIZE="0.5623761809134395" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21337800235715168" LOG_CI_START="-0.7133241660893828" LOG_EFFECT_SIZE="-0.2499730818661155" ORDER="56605" O_E="-1.9424657534246572" SE="0.5443494409952103" STUDY_ID="STD-CAFA" TOTAL_1="181" TOTAL_2="184" VAR="3.37477200225183" WEIGHT="15.419120287415275"/>
<DICH_DATA CI_END="0.6025213500400174" CI_START="0.1133961961446457" EFFECT_SIZE="0.261387890290416" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.22002755947460753" LOG_CI_START="-0.9454015135303956" LOG_EFFECT_SIZE="-0.5827145365025016" ORDER="56606" O_E="-7.390476190476191" SE="0.42608825127135186" STUDY_ID="STD-SPINAF" TOTAL_1="260" TOTAL_2="265" VAR="5.508088141108861" WEIGHT="25.16610708657454"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.573378316047767" CI_END="0.5849603893818194" CI_START="0.1972598415813141" DF="2.0" EFFECT_SIZE="0.33968984933436197" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="41" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.2328735411918834" LOG_CI_START="-0.7049613199926384" LOG_EFFECT_SIZE="-0.4689174305922609" NO="2" P_CHI2="0.7507450802360256" P_Z="9.876610038028936E-5" STUDIES="3" TAU2="0.0" TOTAL_1="713" TOTAL_2="710" WEIGHT="59.414772626010176" Z="3.893603338000335">
<NAME>Open label trials</NAME>
<DICH_DATA CI_END="0.8528701752139752" CI_START="0.16150300256426642" EFFECT_SIZE="0.3711348731857046" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.06911707255961037" LOG_CI_START="-0.7918193991225326" LOG_EFFECT_SIZE="-0.4304682358410714" ORDER="56607" O_E="-5.5" SE="0.4245189240572731" STUDY_ID="STD-AFASAK-I" TOTAL_1="315" TOTAL_2="315" VAR="5.548887122416534" WEIGHT="25.352515057236637"/>
<DICH_DATA CI_END="0.7091978228244836" CI_START="0.07799895685768725" EFFECT_SIZE="0.2351950050193512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.14923260631528823" LOG_CI_START="-1.1079112054374636" LOG_EFFECT_SIZE="-0.6285719058763758" ORDER="56608" O_E="-4.564039408866995" SE="0.5631325546599664" STUDY_ID="STD-BAATAF" TOTAL_1="205" TOTAL_2="201" VAR="3.153397585748529" WEIGHT="14.407674549942294"/>
<DICH_DATA CI_END="1.0207543771378955" CI_START="0.15421261598131364" EFFECT_SIZE="0.3967533273619911" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.008921250914661229" LOG_CI_START="-0.8118800956304294" LOG_EFFECT_SIZE="-0.4014794223578841" ORDER="56609" O_E="-3.9767441860465116" SE="0.4821427739927794" STUDY_ID="STD-SPAF-I" TOTAL_1="193" TOTAL_2="194" VAR="4.30178474851271" WEIGHT="19.654583018831246"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>